ArticleCentral-European journal of immunology2026
Lactylated chitinase-3-like protein 1 promotes the development of sepsis.
Article in Central-European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitinase-3-like protein 1 (CHI3L1) is overexpressed in various types of diseases, particularly in sepsis, and contributes to disease progression. However, the role of CHI3L1 and the pathways involved in the progression of sepsis are not yet completely understood. In the present study, lipopolysaccharide (LPS) was used to construct mouse and cell models of sepsis. Reverse transcription-quantitative PCR was used to detect the expression of CHI3L1. Cycloheximide was used to analyze the protein stability of CHI3L1. The mRNA levels of CHI3L1 and the lactate content were found to be significantly elevated in the serum of patients with sepsis and in LPS-exposed RAW264.7 cells. Furthermore, LPS exposure significantly increased the lactylation of CHI3L1 in RAW264.7 cells. Lactate treatment promoted the lactylation of CHI3L1 and 2-DG treatment inhibited it. Lactylation induced the degradation of CHI3L1 protein. Furthermore, CHI3L1 knockdown inhibited macrophage apoptosis and the release of inflammatory cytokines (IL-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.